Pre-made Atibuclimab benchmark antibody ( Whole mAb, anti-CD14 therapeutic antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-035
Pre-Made Atibuclimab biosimilar, Whole Mab: Anti-CD14 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Atibuclimab (formerly IC 14) is a recombinant chimeric monoclonal antibody being developed by Implicit Bioscience for the treatment of acute lung injury, motor.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Pre-Made Atibuclimab biosimilar, Whole Mab: Anti-CD14 therapeutic antibody|
|Highest_Clin_Trial (Jan '20)||Phase-II|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Companies||ICOS Corporation;Implicit Bioscience|
|Conditions Active||Acute lung injury;COVID-19|
|Conditions Discontinued||Adult respiratory distress syndrome;Motor neuron disease;Septic shock|